For Immediate Release
Chicago, IL – September 9, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Disney DIS, Novo Nordisk NVO, BHP Group BHP, Broadcom AVGO and Eli Lilly LLY.
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Disney, Novo Nordisk and BHP
The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Disney, Novo Nordisk and BHP Group. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Disney shares have outperformed the Zacks Media Conglomerates industry in the year to date period (-6.7% vs. -9.6%). The Zacks analyst believes that Disney has been benefitting from the growing popularity of Disney+, owing to a strong content portfolio and a cheaper bundle offering despite stiff competition.
The availability of Mulan on Disney+ is expected to boost app download. Moreover, upcoming launches in the Nordics, Belgium, Luxembourg, Portugal and Latin America are expected to rapidly expand Disney+’s subscriber base. However, Disney’s businesses continue to be affected by the coronavirus pandemic.
Shanghai Disney Resort re-opened in May and Hong Kong Disneyland Resort, despite reopening in late June, was closed again in July. The pandemic affected Disney’s third-quarter segmental operating income by $3.5 billion. Moreover, a leveraged balance sheet is a significant headwind.
(You can read the full research report on Disney here >>>)
Shares of Novo Nordisk have gained +9.9% over the past six months against the Zacks Large Cap Pharmaceuticals industry’s rise of +8.6%. The Zacks analyst believes that Novo Nordisk has a strong presence in the Diabetes Care market and boasts of a strong pipeline, with focus on therapeutic proteins within insulin. Victoza remains the growth engine for the company.
The initial uptake of Rybelsus looks good. Ozempic, a once-weekly GLP-1, is off to a solid start. The label of Ozempic was further expanded by the FDA to include a cardiovascular indication. Novo Nordisk has one of the broadest diabetes portfolios in the industry. Tresiba, Victoza, Ozempic, Xultophy and Saxenda maintain momentum for the company.
Label expansion of existing drugs will further boost sales for the company. However, lower realized prices in the Unites States, loss of exclusivity for products in hormone replacement therapy and intensifying competition will impact sales. Moreover, the impact of COVID-19 will affect the performance in the upcoming quarters.
(You can read the full research report on Novo Nordisk here >>>)
BHP’s shares have gained +7.2% over the past year against the Zacks Mining – Miscellaneous industry’s rise of +19.3%. The Zacks analyst believes that BHP’s six major projects under development in petroleum, copper, iron ore and potash, will drive growth in the long run.
BHP Group’s fiscal 2020 revenues and earnings declined year over year, and also lagged the respective Zacks Consensus Estimate. Iron ore production rose 4% year over year to a record 248 Mt in fiscal 2020. In fiscal 2021, it expects to produce 244-253 Mt of iron ore. However, the slowdown in global growth due to the impact of the COVID-19 pandemic is likely to impact demand and weigh on results.
Nevertheless, its strong cash flow and focus on lowering debt will help it sail through these turbulent times. The recent surge in iron and copper prices also holds promise. Efforts to make operations more efficient on the back of smarter technology adoption across the entire value chain will bolster margins.
(You can read the full research report on BHP here >>>)
Other noteworthy reports we are featuring today include Broadcom and Eli Lilly.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it’s predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce “the world’s first trillionaires,” but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks’ 3 Best Stocks to Play This Trend >>
Join us on Facbook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Zacks Investment Research